Gholamhossein Sodeifian
University of kashan, Iran
Title: Investigation of magnetotocosome as the magnetic targeting drug delivery system for Sorafenib tosylate anticancer drug
Biography
Biography: Gholamhossein Sodeifian
Abstract
Hepato-Cellular Carcinoma (HCC) is the fifth prevalent malignant tumor having the third rank in the global mortality chart. Sorafenib tosylate (SFB) is approved as the first anticancer drug for the treatment of HCC. According to the Biopharmaceutical Classification Scheme (BCS), SFB belongs to class II compounds that indicate a very poor solubility in the aqueous solution at different pH values from pH=1.2 to pH=7.4 (slow dissolution rate within the gastrointestinal tracts) and high permeability from the gastrointestinal lumen. The drug has low oral bioavailability (8.43%); consequently, high dose treatment is necessary which may cause the systemic toxicity [Figure 1]. Nanotechnology based novel drug delivery systems are applied to design the systems with improved biocompatibility and biodegradability which can deliver the drug molecule efficiently and safely to the target tissue thus decrease the side effects, especially for drugs with narrow therapeutic index or cytotoxic effects.